Dr Laffin serves/served as a consultant or on steering committees for Recor, Medtronic, Eli Lilly, Mineralys, Crispr Therapeutics, Idorsia, Novo Nordisk, Arrowhead Pharmaceuticals, Ripple Medical, and Stability Health. He has received research funding from AstraZeneca for studies of rosuvastatin. He receives royalties from Belvoir Media Group, Elsevier, and Springer Nature. No personal renumeration is received for work with Mineralys. Funds are paid to C5 Research, the academic research organization of the Heart, Vascular, and Thoracic Institute of the Cleveland Clinic.